Guidelines on the diagnosis and management of AL amyloidosis

被引：96

作者：

Bird, J

Cavenagh, J

Hawkins, P

Lachmann, H

Mehta, A

Samson, D

机构：

[1] Bristol Haematol & Oncol Ctr, Avon Haematol Unit, Bristol BS2 3ED, Avon, England

[2] Royal Free Hosp, St Bartholomews & Royal London Sch Med & Dent, London NW3 2QG, England

[3] Royal Free Hosp, Natl Amyloidosis Ctr, London NW3 2QG, England

[4] Univ London Imperial Coll Sci Technol & Med, London, England

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2004年 / 125卷 / 06期

关键词：

AL amyloidosis; treatment; diagnosis; chemotherapy; stem cell transplantation;

D O I：

10.1111/j.1365-2141.2004.04970.x

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

[No abstract available]

引用

页码：681 / 700

页数：20

共 63 条

[1]

Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL) [J].

Abraham, RS ;

Geyer, SM ;

Price-Troska, TL ;

Allmer, C ;

Kyle, RA ;

Gertz, MA ;

Fonseca, R .

BLOOD, 2003, 101 (10) :3801-3808

[2]

VAD-BASED REGIMENS AS PRIMARY-TREATMENT FOR MULTIPLE-MYELOMA [J].

ALEXANIAN, R ;

BARLOGIE, B ;

TUCKER, S .

AMERICAN JOURNAL OF HEMATOLOGY, 1990, 33 (02) :86-89

[3]

Bradwell AR, 2001, CLIN CHEM, V47, P673

[4]

RESOLUTION OF ACQUIRED FACTOR-X DEFICIENCY AND AMYLOIDOSIS WITH MELPHALAN AND PREDNISONE THERAPY [J].

CAMORIANO, JK ;

GREIPP, PR ;

BAYER, GK ;

BOWIE, EJW .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (18) :1133-1135

[5]

Thalidomide in multiple myeloma: Current status and future prospects [J].

Cavenagh, JD ;

Oakervee, H .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (01) :18-26

[6]

Autologous stem cell transplantation for primary systemic amyloidosis [J].

Comenzo, RL ;

Gertz, MA .

BLOOD, 2002, 99 (12) :4276-4282

[7]

Comenzo RL, 1998, BLOOD, V91, P3662

[8]

Treatment of AL-amyloidosis with dexamethasone plus alpha interferon [J].

Dhodapkar, MV ;

Jagannath, S ;

Vesole, D ;

Munshi, N ;

Naucke, S ;

Tricot, G ;

Barlogie, B .

LEUKEMIA & LYMPHOMA, 1997, 27 (3-4) :351-356

[9]

Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival [J].

Dispenzieri, A ;

Lacy, MQ ;

Kyle, RA ;

Therneau, TM ;

Larson, DR ;

Rajkumar, SV ;

Fonseca, R ;

Greipp, PR ;

Witzig, TE ;

Lust, JA ;

Gertz, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3350-3356

[10]

DUBREY S, 1995, BRIT HEART J, V74, P541

← 1 2 3 4 5 6 7 →